Li Gui-Zhi, Liu Jia-Yin, Zhou Hong
Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China.
World J Diabetes. 2025 Jun 15;16(6):104665. doi: 10.4239/wjd.v16.i6.104665.
Ferroptosis is a new type of programmed cell death caused by the accumulation of iron-dependent lipid peroxides, and it plays a role in the occurrence and progression of diverse diseases. Diabetic cardiomyopathy (DCM), a serious cardiovascular complication in patients with diabetes, eventually progresses to refractory heart failure (HF), which increases the risk of hospitalization for HF and cardiovascular death in patients with diabetes. Despite glycemic control, effective strategies to prevent DCM onset are currently lacking. Accumulating evidence suggests that ferroptosis is involved in oxidative stress, inflammation, and abnormal autophagy in diabetic myocardium, which plays an important role in myocardial apoptosis, hypertrophy, and cardiac fibrosis. The inhibition of ferroptosis can relieve DCM. Presently, ferroptosis inhibitors have been broadly suggested for the treatment of iron overload-related cardiomyopathy. This article reviewed relevant studies to offer a new therapeutic target for DCM.
铁死亡是一种由铁依赖性脂质过氧化物积累引起的新型程序性细胞死亡，在多种疾病的发生和发展中起作用。糖尿病性心肌病（DCM）是糖尿病患者的一种严重心血管并发症，最终会发展为难治性心力衰竭（HF），这增加了糖尿病患者因HF住院和心血管死亡的风险。尽管进行了血糖控制，但目前仍缺乏预防DCM发病的有效策略。越来越多的证据表明，铁死亡参与了糖尿病心肌中的氧化应激、炎症和自噬异常，这在心肌细胞凋亡、肥大和心脏纤维化中起重要作用。抑制铁死亡可以缓解DCM。目前，铁死亡抑制剂已被广泛建议用于治疗铁过载相关的心肌病。本文综述了相关研究，为DCM提供了一个新的治疗靶点。
